Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13047
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNayler, W Gen
dc.date.accessioned2015-05-16T02:49:25Z
dc.date.available2015-05-16T02:49:25Z
dc.date.issued1994-05-16en
dc.identifier.citationJournal of Cardiovascular Pharmacology; 24 Suppl A(): S12-7en
dc.identifier.govdoc7603072en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/13047en
dc.description.abstractHypertension is a complex disease, the treatment of which should not only lower systolic and diastolic blood pressure but also attenuate the secondary consequences of the disease. These include vascular injury (including atherosclerosis), stroke, left ventricular hypertrophy, and renal damage. To establish whether the long-acting, vascular-selective calcium antagonist amlodipine attenuates some of these secondary consequences of hypertension, 5-week-old stroke-prone hypertensive and 8-week-old spontaneously hypertensive rats were treated (orally) with 5 mg/kg/day and 10 mg/kg/day amlodipine, respectively, for 30 weeks. The treatment resulted in a significant lowering of systolic blood pressure, accompanied by reduced cardiac hypertrophy and prolonged survival. Evidence for a protective effect of amlodipine on the vasculature was obtained by treating cholesterol-fed rabbits with 1-5 mg/kg/body weight/day. This resulted in a reduction in vascular Ca2+ overloading and a reduced incidence of sudanophilic lesion formation. Protection against ischemia-induced changes in the myocardium included a reduction in the ischemia-induced externalization of endothelin-1 binding sites.en
dc.language.isoenen
dc.subject.otherAdministration, Oralen
dc.subject.otherAmlodipine.administration & dosage.pharmacology.therapeutic useen
dc.subject.otherAnimalsen
dc.subject.otherAorta, Thoracic.drug effects.metabolism.pathologyen
dc.subject.otherArteriosclerosis.etiology.prevention & controlen
dc.subject.otherBinding Sitesen
dc.subject.otherBlood Pressure.drug effectsen
dc.subject.otherCalcium.analysisen
dc.subject.otherCardiomegaly.mortality.prevention & controlen
dc.subject.otherCholesterol.analysisen
dc.subject.otherCholesterol, Dietary.administration & dosageen
dc.subject.otherDisease Models, Animalen
dc.subject.otherEndothelins.metabolismen
dc.subject.otherHypertension.complications.drug therapy.mortalityen
dc.subject.otherMaleen
dc.subject.otherMyocardial Ischemia.drug therapy.metabolismen
dc.subject.otherMyocardial Reperfusion Injury.drug therapy.metabolismen
dc.subject.otherRabbitsen
dc.subject.otherRatsen
dc.subject.otherRats, Inbred SHRen
dc.subject.otherRats, Inbred WKYen
dc.titleEnd-organ involvement and calcium antagonist therapy: animal studies.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of Cardiovascular Pharmacologyen
dc.identifier.affiliationDepartment of Medicine, University of Melbourne, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pagesS12-7en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/7603072en
dc.type.austinJournal Articleen
item.grantfulltextnone-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.